Kyung Dong Pharmaceutical Co., Ltd.

KOSDAQ:A011040 Stock Report

Market Cap: ₩163.3b

Kyung Dong Pharmaceutical Valuation

Is A011040 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A011040 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A011040 (₩6110) is trading above our estimate of fair value (₩5930.51)

Significantly Below Fair Value: A011040 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A011040?

Key metric: As A011040 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A011040. This is calculated by dividing A011040's market cap by their current revenue.
What is A011040's PS Ratio?
PS Ratio0.9x
Sales₩189.19b
Market Cap₩163.27b

Price to Sales Ratio vs Peers

How does A011040's PS Ratio compare to its peers?

The above table shows the PS ratio for A011040 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.9x
A060590 CTCBIO
1.2xn/a₩169.5b
A002390 HANDOK
0.3xn/a₩178.1b
A106190 High Tech Pharm
1.8xn/a₩150.5b
A271980 Jeil PharmaceuticalLtd
0.3xn/a₩179.5b
A011040 Kyung Dong Pharmaceutical
0.9xn/a₩163.3b

Price-To-Sales vs Peers: A011040 is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (0.9x).

Price to Sales Ratio vs Industry

How does A011040's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
A009290 Kwang Dong Pharmaceutical
0.1xn/aUS$161.67m
A002620 Jeil Pharma Holdings
0.2xn/aUS$94.48m
A000230 Ildong Holdings
0.1xn/aUS$56.43m
No more companies available in this PS range
A011040 0.9xIndustry Avg. 0.8xNo. of Companies15PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A011040 is expensive based on its Price-To-Sales Ratio (0.9x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A011040's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A011040 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A011040's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

J2KBIO

₩54.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,830.00

7D

6.0%

1Y

n/a

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,000.00

7D

-3.4%

1Y

75.9%

Dong-A ST

₩544.1b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩62,300.00

7D

-2.0%

1Y

8.6%